Soluble and Cell-Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma.

about

Soluble and Cell-Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma.

Item

http://www.wikidata.org/entity/Q55091606

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Soluble and Cell-Cell-Mediated ...... esistance in Multiple Myeloma.

@en

Soluble and Cell-Cell-Mediated ...... esistance in Multiple Myeloma.

@nl

type

Item

label

Soluble and Cell-Cell-Mediated ...... esistance in Multiple Myeloma.

@en

Soluble and Cell-Cell-Mediated ...... esistance in Multiple Myeloma.

@nl

prefLabel

Soluble and Cell-Cell-Mediated ...... esistance in Multiple Myeloma.

@en

Soluble and Cell-Cell-Mediated ...... esistance in Multiple Myeloma.

@nl

P1476

Soluble and Cell-Cell-Mediated ...... esistance in Multiple Myeloma.

@en

P2093

Mariah L Farrell

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular mechanisms of bortezomib resistant adenocarcinoma cells

Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma.

NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma.

Engineered nanomedicine for myeloma and bone microenvironment targeting.

The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells.

Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.

Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.

Review of 1027 patients with newly diagnosed multiple myeloma.

Anticancer drug bortezomib increases interleukin-8 expression in human monocytes.

P304

218

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FENDO.2018.00218

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michaela R. Reagan

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29765356

http://www.w3.org/2001/XMLSchema#string

P932

5938346

http://www.w3.org/2001/XMLSchema#string